New treatment recommendations for children with Acute Lymphoblastic Leukemia
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
This study is testing new treatment guidelines for children with Acute Lymphoblastic Leukemia to see if they can help more kids go into remission and stay cancer-free.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | French Africa Pediatric Oncology Group Academic / other |
| Drugs / interventions | chemotherapy, Methotrexate |
| Locations | 3 sites (Abidjan and 2 other locations) |
| Trial ID | NCT04794296 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the implementation of new treatment recommendations for children diagnosed with Acute Lymphoblastic Leukemia (ALL). It focuses on both standard and high-risk forms of ALL, introducing anthracycline induction and high-dose consolidation therapies. The study seeks to ensure the feasibility of these recommendations and aims for a complete remission rate of approximately 85% after induction treatment. Additionally, it will assess the long-term survival without relapse in patients achieving remission.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 0 to 18 years who are newly diagnosed with ALL and have not received prior chemotherapy.
Not a fit: Patients with ALL L3 (Burkitt), those previously treated with chemotherapy, or those with Trisomy 21 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve treatment outcomes and survival rates for children with Acute Lymphoblastic Leukemia.
How similar studies have performed: Previous studies in developing countries have shown that tailored treatment protocols can significantly improve outcomes for children with ALL, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2 \- Exclusion Criteria: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Where this trial is running
Abidjan and 2 other locations
- CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (Recruiting)
- CHU Donka 030 BP 554 — Conakry, Guinea (Recruiting)
- Hôpital Aristide Le Dantec, Avenue Pasteur, — Dakar, Senegal (Recruiting)
Study contacts
- Study coordinator: Ndella Ms DIOUF, MD
- Email: ndella.diouf@gfaop.org
- Phone: 00(221)77 656 49 13.
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.